cemiplimab-rwlc (LIBTAYO)
Antineoplastic Agent | Immune Checkpoint Inhibitor
Dosing and Administration
- The recommended dosage is 350 mg administered as an intravenous infusion over 30 minutes every 3 weeks.
- Treatment should be continued until disease progression or unacceptable toxicity.
- No dose reductions are recommended. Dosing may be withheld or discontinued to manage adverse reactions.
Indications
Cemiplimab-rwlc is indicated for:
- Cutaneous squamous cell carcinoma (CSCC) that has spread or cannot be cured by surgery/radiation
- Basal cell carcinoma (BCC) after treatment with a hedgehog pathway inhibitor
- First-line treatment of advanced non-small cell lung cancer (NSCLC), either as monotherapy or in combination with chemotherapy
Key Adverse Effects
- Immune-mediated adverse reactions affecting multiple organ systems can occur and may be severe or fatal.
- Common adverse reactions include fatigue, rash, diarrhea, musculoskeletal pain, and nausea.
Monitoring
- Monitor liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment.
- Assess for signs/symptoms of immune-mediated reactions affecting the lungs, intestines, liver, hormonal glands, skin, or kidneys.
Patient Education
- Advise patients to report any new or worsening symptoms promptly.
- Inform patients about potential infusion-related reactions.
- Counsel females of reproductive potential on the need for effective contraception during treatment and for 4 months after the last dose.
Administration Pearls
- Administer through an IV line containing a sterile, in-line or add-on 0.2-micron to 5-micron filter.
- Do not co-administer other medications through the same infusion line.
- Monitor patients for infusion-related reactions, especially during and after the first infusion.
References:
[1] https://medlineplus.gov/druginfo/meds/a618054.html
[2] https://www.regeneron.com/downloads/libtayo_fpi.pdf
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761097s001lbl.pdf
[4] https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761097s014lbl.pdf
[5] https://www.libtayo.com/sfsites/c/resource/libtayo_consumer_downloads/patient/patient-brochure-cscc.pdf
[6] https://www.mayoclinic.org/drugs-supplements/cemiplimab-rwlc-intravenous-route/proper-use/drg-20444105?p=1
[7] https://www.libtayohcp.com
[8] https://www.libtayo.com/nsclc/support-and-resources
[9] https://libtayo.com/nsclc/taking-libtayo
Did you find this clinical pearl helpful?